|
Market Closed -
Nasdaq Stockholm
02:00:00 01/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 1.792 SEK | +0.22% |
|
+3.34% | -9.04% |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 266.5 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 59.26% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 266.5 | 266.5 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 59.26% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 2.63x | 1.86x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.63x | 1.86x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -9.38x | 6.9x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -8.49x | 7.7x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.788 | 1.788 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 23/2/22 | 23/2/23 | 7/2/24 | 12/2/25 | 25/2/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 27.74M | |
| 33.44x | 12.14x | 24.6x | 0.59% | 1,047B | |
| 29.82x | - | - | 2% | 646B | |
| 32.61x | 7.57x | 15.74x | 2.68% | 451B | |
| 19.99x | 4.75x | 11.76x | 2.79% | 355B | |
| 21.76x | 5.62x | 13.93x | 2.85% | 291B | |
| 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.35x | 7.07x | 12.56x | 2.33% | 234B | |
| 13.25x | 4.77x | 9.95x | 3.83% | 203B | |
| -44.51x | 6.43x | 25.11x | 2.26% | 181B | |
| Average | 17.17x | 6.58x | 15.74x | 2.38% | 365.93B | |
| Weighted average by Cap. | 24.24x | 8.07x | 17.81x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
